65,437 trials
Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Myelodysplastic Syndromes
Primary: Number of Participants Achieving Graft-versus-Host Disease-Free and Relapse-Free Survival (GRFS) Through 1 Year Post-Transplant — 4 Participants
Obesity
Primary: Weight Loss — 24.04 percent who lost 5% or more weight — p=<0.05
Adenocarcinoma of the Pancreas · Metastatic Pancreatic Cancer · Pancreatic Cancer
Primary: Number of Participants With Dose Limiting Toxicities (DLTs; Phase 1b Portion Only) — 0; 0 Participants
Osteoarthritis · Avascular Necrosis · Rheumatoid Arthritis
Primary: Harris Hip Score — 50.0; 80.6; 94.5; 94.5 score on a scale
Asthma in Children · Pollution; Exposure
Primary: Continuously-Measured Home PM2.5 (Fine Particulate Matter) Levels Prior to Intervention — 10200 (mcg/m3)*min — p=0.050
Temperature Change, Body
Primary: Agreement Between Different Core Temperature Methods — 35.0; 35.2; 35.6; 34.8 celsius degrees (mean difference)
Major Depressive Disorder · Bipolar Disorder
Primary: Total Score on the Hamilton Rating Score for Depression (HRSD) - 21 Item Version — 19; 18.5; 10.2; 14.4 Total score on a scale — p=<0.05
Lung Cancer
Primary: Clinically Significant Event (CSE) — 0.425 Proportion of subjects — p=< .0001
Primary Progressive Aphasia
Primary: Change in Communication Confidence (CCRSA) — 72.6; 72.9; 73.7; 74.5 units on a scale
Chronic Hand Eczema
Primary: Number of Participants With IGA-CHE TS at Week 16 — 91; 11 Participants — p=<0.001
HIV I Infection
Primary: The Primary Outcome Measure is to Evaluate the Efficacy of Switching From B/F/TAF to DTG/3TC Versus Continuing B/F/TAF as Determined by the Proportion of Participants…
Postoperative Hypoparathyroidism · Thyroid Neoplasms · Thyroid Cancer
Primary: Average Number of Parathyroid Glands Identified With High Confidence Per Patient — 2.81; 2.75 parathyroid glands — p=0.6905
Malaria
Primary: The Tolerability and Safety of Ascending Single Oral Doses of MMV533 — 5; 3; 7; 4 participants
Stroke
Primary: Percentage of Patients With Favourable Outcome (Modified Rankin Scale (mRS) 0-1) at 1 Year — 27.7; 23.8 Percentage of Participants — p=<0.001
Paraganglioma · Pheochromocytoma
Primary: Clinical Benefit Rate (CBR) Which is Defined as Either a Partial Response (PR) Complete Response (CR) or Stable Disease (SD) for ≥ 12 Weeks Measured Using Response…